PharmExec Direct Marketing Edition

1 - 'Average Wholesale Price' Means Lawsuits for Pharma

2 - And in this corner ...

3 - On the Right Track

4 - Barr to Pharma: 'Watch Out'

5 - Big Growth in Small Markets

6 - Oral Diabetes Race Comes Down to Marketing

7 - Downer for SSRI Makers

8 - Gilead Embraces Change

9 - Roche One-Ups Partner

10 - Shire, Barr Swap Drugs, Not Money

11 - D-Day

12 - Fast Forward

13 - 'Merck Did Nothing Wrong,' Martin Report says

14 - PBMs Liked Zocor Deal

15 - Schering-Plough Settlement Represents Third Largest Against Pharma

16 - Federal Courts Get Tough on Patents

17 - Merck Defends Vioxx Strategy, Releases Arcoxia Data

18 - Nasonex Bee Buzzes New Message

19 - BMS, Sanofi Sign Away Key Plavix Rights

20 - Pharma-Biotech M&A Prices Nearly Triple

21 - Vaccine Development Stagnates

22 - Sandoz Deal Leads Quest for Follow-on Biologics

23 - Jeffrey Kindler: In His Own Words

24 - Prescribing Data: It's a Matter of Free Speech

25 - Abbott, AstraZeneca Join Race to Develop Combo Cholesterol Drug

26 - Small Percentage of Physicians Enroll in PDRP

27 - Updated: Barr Bids to Become Third Largest Generics Maker

28 - Drug Makers Reach Independent Pharmacists

29 - J&J Shows Pfizer the Money

30 - Merck Slashes Zocor Price

31 - Sandoz Brings Test Case for Biogenerics

32 - FDA Mandates Adoption of Tracking Systems

33 - Novartis Developing Next Generation of Malaria Drugs

34 - ASCO Showcases Competition Between Big Pharma, Biotech

35 - Medicare Part D Spurs Greater Demand for Generics

36 - Wyeth Petitions FDA on Bioidentical Hormones

37 - Anthrax Contract Dispute Could Reverberate Across Biotech Industry

38 - AstraZeneca Sets Sights on Biologics Company

39 - Roche Hires Ad Agency for Tamiflu

40 - Court ruling finds terminally ill patients have right to unapproveddrugs

41 - Two patent rulings raise issues for biotechs, generics

42 - Watching the Supply Chain

43 - Court Says Agency Must Decide on Generic HGH

44 - Why COX-2 Inhibitors Hurt the Heart

45 - New Licensing and Development Agreements

46 - Commuting Plays a Major Role in the Spread of Influenza

47 - Novartis Ups Bid for Chiron

48 - Study Compares Schizophrenia Treatments

49 - HIV-produced Protein Decreases Antibody Specificity

50 - Label Changes Would Have Minimal Impact on ADHD Market

51 - Lawsuit Alleges Pfizer Marketed Lipitor Too Broadly

52 - Supreme Court Hears Arguments in Patent Case

53 - Advisory Committee Recommends Tysabri Return

54 - Study Shows Development Time Decreasing

55 - Sudden Infant Death Syndrome Linked to Serotonin

56 - Supreme Court Will Decide if MedImmune Can Sue Genentech

57 - Weight May Influence Response to Asthma Treatments

58 - Acomplia Approval Delayed

59 - 850 Generic Drugs Awaiting Approval

60 - Common Antidepressants Increase Risk of Infant Respiratory Disorder

61 - The First Plant-Derived Vaccine Approved for Chickens

62 - BMS Reserves $185 Million for Vanlev Suit

63 - Popular Web Site Used to Predict Epidemic Patterns

64 - ImClone Searches for Potential Buyer

65 - FDA Encourages Exploratory Human Testing

66 - Pfizer Adds Radio Frequency Identification Tags to Viagra

67 - Understanding Demand, Not Just Supply, Key to Solving Flu Vaccine Shortages

68 - Genetic Research Yields Controversial Parkinsons Drug Target

69 - Physician Calls for Guidelines on Tamiflu Stockpiling

70 - Researchers Use Transgenic Plants to Produce Anthrax Vaccine

71 - Analysis Confirms Medication is as Effective as Surgery for Acid Reflux

72 - Los Angeles Facility Discontinues Use of OraQuick Rapid HIV Test

73 - Study Will Compare Heart Risk of COX-2 and NSAIDs

74 - Merck Will Lay Off 7,000 and Close Five Plants

75 - Microbiology Research Could Lead to Improved TB Treatment

76 - Preclinical Goes Digital

77 - Animal Rights Activists Create PR Crisis

78 - What Really Happened to Pargluva

79 - Patients Are Playing Doctor on the Web. It is a Whole New Game for Pharma.

80 - Advisory Committee Recommends Hepatitis A Vaccine for All Children

81 - Merck Wins Round Two

82 - FDA to Collaborate to Find Biomarker for Liver Toxicity

83 - Advisory Committee to Review OTC HIV Test

84 - Predicting the Success of HPV Vaccines

85 - Atypical Antipsychotics Increase Risk of Death for Dementia Patients

86 - Predicting the Success of HPV Vaccines

87 - Generic AZT Hits the United States

88 - Human Genome Sciences Awarded Contract for Anthrax Drug

89 - Blood Advisory Committee Recommends Exjade by Novartis

90 - Andrew von Eschenbach Appointed New Acting Head of FDA

91 - California Researchers Investigate Antibody-like Viral Protein

92 - Anti-Inflammatory Treatment Could Change as a Result of New Findings on Nuclear Receptor Proteins

93 - Arthritis Advisory Committee Recommends Orencia by Bristol-Myers Squibb

94 - Study Shows Faster Approval Does Not Affect Safety

95 - FDA Approves Genetic Test to Customize Dosage for Pfizer Cancer Drug

96 - Merck Found Liable in First Vioxx Trial

97 - Placebo Effect: All in the Brain

98 - Acambis Working to Create a Universal Flu Vaccine

99 - Pozen Files NDA Days After Advisory Committee Rejection

100 - Two New Techniques Make Genome Sequencing Faster and Cheaper

101 - CAFTA Intellectual Property Provisions Stir Controversy

102 - Teva Advances Generics Consolidation with Ivax Purchase

103 - Sleep Aid with Novel Mechanism Approved

104 - Brazil Uses Compulsory Licensing Threat in Negotiations

105 - Prescription Drug Addiction Study Recommends Marketing Sensitivity

106 - Vision Problem Added to Labels for Viagra, Cialis, and Levitra

107 - Californians to Vote on Drug Discount Plan

108 - GSK Inks Deal with Non-Profit to Develop AIDS Vaccine

109 - Supreme Court: Research Use of Patented Compounds OK

1 - 'Average Wholesale Price' Means Lawsuits for Pharma

Judge defines term ahead of Medicare fraud trial.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=384434

2 - And in this corner ...

Abbott's acquisition of Kos creates a viable contender in the fight for cardiovascular market share.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=384422

3 - On the Right Track

After decades of disparate attempts to secure supply chains, pharma companies may finally be getting on the same page.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=384473

4 - Barr to Pharma: 'Watch Out'

After winning a bidding war for Pliva, the well-positioned generic maker is giving pharma reason to worry.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=381483

5 - Big Growth in Small Markets

Emerging countries are expected to drive pharma's earnings next year.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=381487

6 - Oral Diabetes Race Comes Down to Marketing

Merck's Januvia has a head start, but Novartis isn't sitting idle.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=381499

7 - Downer for SSRI Makers

JAMA study questions effectiveness of popular antidepressants.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=378218

8 - Gilead Embraces Change

After axing oncology, Gilead says it's ready for new therapeutic areas.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=378223

9 - Roche One-Ups Partner

Drug giant beefs up early-stage R&D, moving into Genentech's turf.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=378152

10 - Shire, Barr Swap Drugs, Not Money

The recent settlement between branded and generic companies offers a 'win-win' approach to patent challenges.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=374916

11 - D-Day

The Part D donut hole has arrived, and pharma is scrambling to maintain brand loyalty.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=374944

12 - Fast Forward

A new, faster recipe for drug development: Chat up regulators. Outsource where you can. And know when to let go.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=374911

13 - 'Merck Did Nothing Wrong,' Martin Report says

Company-commissioned report exonerates senior managers, points fingers at sales team

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=371209

14 - PBMs Liked Zocor Deal

Drug makers used aggressive contracting to retain marketshare after launch of generic simvastatin

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=371226

15 - Schering-Plough Settlement Represents Third Largest Against Pharma

Pricing, marketing cases expected to escalate in the future

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=371245

16 - Federal Courts Get Tough on Patents

Recent analysis shows partial or complete invalidation of all pharma patents challenged since December 2004.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=368223

17 - Merck Defends Vioxx Strategy, Releases Arcoxia Data

Company faces two Vioxx setbacks in court as it prepares to reveal safety data on its cox-2 successor.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=368226

18 - Nasonex Bee Buzzes New Message

Schering-Plough's successful allergy medication gets an updated ad campaign.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=368026

19 - BMS, Sanofi Sign Away Key Plavix Rights

Legal experts question how reverse payment deal went so awry.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=365537

20 - Pharma-Biotech M&A Prices Nearly Triple

Biotechs find sales more profitable than IPOs.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=365544

21 - Vaccine Development Stagnates

Bioterrorism and larger profit margins could drive future growth.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=365549

22 - Sandoz Deal Leads Quest for Follow-on Biologics

Partnership with Momenta includes technology to evaluate bio-equivalence.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=362116

23 - Jeffrey Kindler: In His Own Words

Pfizer's new CEO shares his views on a range of hot topics, from sales and marketing to regulation, compliance, and corporate culture.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=362035

24 - Prescribing Data: It's a Matter of Free Speech

IMS and Verispan's New Hampshire lawsuit argues right to share prescribing data.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=362117

25 - Abbott, AstraZeneca Join Race to Develop Combo Cholesterol Drug

Deal combines Crestor with either TriCor or experimental fibrate.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=359149

26 - Small Percentage of Physicians Enroll in PDRP

AMA says enrollment depends on physicians' experiences with drug reps.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=359195

27 - Updated: Barr Bids to Become Third Largest Generics Maker

Sale of Croatian company Pliva sparks interest from Barr, Actavis.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=359135

28 - Drug Makers Reach Independent Pharmacists

McKesson's new program helps build bridges.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=352991

29 - J&J Shows Pfizer the Money

Drug giants explain sale of Pfizer's consumer business.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=352980

30 - Merck Slashes Zocor Price

Branded drug makers hand generic companies a new challenge.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=352986

31 - Sandoz Brings Test Case for Biogenerics

Approval of Omnitrope ignites debate on whether any precedent was set

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=337643

32 - FDA Mandates Adoption of Tracking Systems

Agency hopes to speed implementation of RFID

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=337649

33 - Novartis Developing Next Generation of Malaria Drugs

Studies of gene-based therapies being funded through public-private partnership

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=337638

34 - ASCO Showcases Competition Between Big Pharma, Biotech

Small molecules are an increasingly viable option for cancer therapeutics

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=333123

35 - Medicare Part D Spurs Greater Demand for Generics

Medicare Part D has increased drug sales and payers are still trying to hold down costs.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=333113

36 - Wyeth Petitions FDA on Bioidentical Hormones

Increased demand for plant-based hormones has spurred Wyeth to ask FDA to set marketing limits on compounded therapies

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=333115

37 - Anthrax Contract Dispute Could Reverberate Across Biotech Industry

VaxGen asks HHS for compensation after the agency modifies testingrequirements

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=328329

38 - AstraZeneca Sets Sights on Biologics Company

AstraZeneca purchases CAT, taps into growing biologics market

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=327984

39 - Roche Hires Ad Agency for Tamiflu

Marketing campaign is the first consumer-focused effort for theantiviral drug in recent years

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=328331

40 - Court ruling finds terminally ill patients have right to unapproveddrugs

Judges' decision finds constitutional right to experimental drugswhen no other options are available

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=325221

41 - Two patent rulings raise issues for biotechs, generics

Courts decide patent disputes regarding natural processes, generic drug challenges

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=325237

42 - Watching the Supply Chain

How can FDA track billions of prescription drugs from manufacturerto patient? Paul Chang, leader of IBM?s RFID program, imagines athin database in the sky.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=325250

43 - Court Says Agency Must Decide on Generic HGH

A federal district court ruled that FDA cannot fail to rule on aSandoz's application for approval of omnitrope, a human growthhormone, just because it has no policy for generic biologics. Courtwatchers say the decision may help other generic biologics moveforward in the approvals process.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=322068

44 - Why COX-2 Inhibitors Hurt the Heart

A new study details the physiological reasons why COX-2inhibitorsincrease the risk of heart disease. Suppressing theproduction of one key fact does reduce pain, but it also deprivesthe body of a mechanism to curb blood clots, resist arteryhardening, and regulate blood pressure.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=322059

45 - New Licensing and Development Agreements

During the past two weeks, companies from a half dozen states andthree foreign lands joined forces. Here?s an update on who?sworking with whom.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=322071

46 - Commuting Plays a Major Role in the Spread of Influenza

New research shows that travel to and from work is important in spreading influenza from city to city and state to state.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=318729

47 - Novartis Ups Bid for Chiron

Industry experts weigh in on what could be the resolution of a long saga.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=318728

48 - Study Compares Schizophrenia Treatments

Psychiatrists offer insight on the second phase of results from a National Institutes of Health study comparing different anti-psychotic drugs.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=318727

49 - HIV-produced Protein Decreases Antibody Specificity

A new study indicates that a protein produced by HIV invades uninfected B cells and inhibits a mechanism that makes certain antibodies very good at targeting invading agents.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=315829

50 - Label Changes Would Have Minimal Impact on ADHD Market

Experts say proposed label changes or black box warnings would not significantly decrease ADHD drug prescriptions. But they see potential market opportunities for new products and generics.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=315827

51 - Lawsuit Alleges Pfizer Marketed Lipitor Too Broadly

A Q&A with Geoffrey Jarvis, counsel for the plaintiffs, with a response from Pfizer.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=315823

52 - Supreme Court Hears Arguments in Patent Case

The high court could fine-tune the definition of what is patentable in deciding LabCorp v. Metabolite. Legal experts weigh-in on the nuances of the case.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=315824

53 - Advisory Committee Recommends Tysabri Return

The recommendation shows traditional risk-benefit analysis is still working, experts say. But they also believe the Tysabri saga illustrates a trend towards increased use of advisory committees and requirements for drug mechanism data.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=312419

54 - Study Shows Development Time Decreasing

Economists discuss a recent article in Health Affairs, which argues that market demands, not R&D costs, determine drug prices.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=312421

55 - Sudden Infant Death Syndrome Linked to Serotonin

A University of Chicago professor explains his findings that serotonin induces gasping in oxygen-deprived infants. These results will probably not lead to Prozac prescriptions for babies, but they could be used to find a genetic marker for SIDS risk down the road.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=312423

56 - Supreme Court Will Decide if MedImmune Can Sue Genentech

The high court’s decision on this licensing dispute could have far-reaching implications for patent negotiations, legal experts say.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=309929

57 - Weight May Influence Response to Asthma Treatments

An analysis of Merck’s clinical trial data for Singular (montelukast) indicates that obese people may respond to asthma treatments differently than lean people. A University of Michigan professor explains his recently published paper.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=309932

58 - Acomplia Approval Delayed

FDA pushed back the expected approval of this would-be blockbuster by giving manufacturer Sanofi-Aventis one ?approvable? letter and one non-approval. Analysts say the drug?s success depends on approval for more indications, and delay could give advantage to a competitor in the smoking-cessation category.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=309930

59 - 850 Generic Drugs Awaiting Approval

Generic drug advocates say flat funding for the Office of Generic Drugs in the 2007 FY budget will do nothing to decrease the growing backlog of products waiting for approval. They claim other streamlining techniques will not reverse this trend.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=307472

60 - Common Antidepressants Increase Risk of Infant Respiratory Disorder

One percent of mothers taking SSRI’s during the second half of pregnancy gave birth to babies with pulmonary hypertension, a recent study found. But the mechanisms that connect increased serotonin with this disorder are unknown.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=307469

61 - The First Plant-Derived Vaccine Approved for Chickens

The door to growing vaccine proteins in plants is officially opened with a USDA-approved veterinary product. Is the FDA prepared for human vaccines grown in plants?

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=307471

62 - BMS Reserves $185 Million for Vanlev Suit

The class action settlement illustrates a trend toward increased transparency, lawyers say. But issues about timing clinical trial disclosures are still unresolved.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=301531

63 - Popular Web Site Used to Predict Epidemic Patterns

An entertaining Internet program that allows Americans to see where a dollar goes after they spend it, helped scientists develop a formula for how infectious diseases spread geographically in United States.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=301532

64 - ImClone Searches for Potential Buyer

Upcoming competition, a weak pipeline, and existing marketing agreements limit the pool of prospective buyers, experts say.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=301530

65 - FDA Encourages Exploratory Human Testing

Observing drug candidates in humans early in the development process could save investigators time and money, experts say.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=283405

66 - Pfizer Adds Radio Frequency Identification Tags to Viagra

Learn how RFID technology works and what it could mean for pharmacies down the road.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=283408

67 - Understanding Demand, Not Just Supply, Key to Solving Flu Vaccine Shortages

Q&A with supply chain expert Prashant Yadav, lead investigator on a study of how to improve flu vaccine distribution.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=283406

68 - Genetic Research Yields Controversial Parkinsons Drug Target

Two experts are split over the importance of research on a gene linked with a rare genetic type of Parkinson’s disease. One thinks it could hold the key to new treatment. The other thinks it is too rare to be relevant.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=279282

69 - Physician Calls for Guidelines on Tamiflu Stockpiling

Q&A with Dr. Allan Brett, professor at the University of South Carolina and director of the General Internal Medicine division. He authored a recent perspective about on-demand Tamiflu prescriptions in the New England Journal of Medicine.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=279279

70 - Researchers Use Transgenic Plants to Produce Anthrax Vaccine

In order to increase production and lower the costs of making anthrax vaccines, a research team grew a protein from anthrax bacteria in tobacco leaves.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=279280

71 - Analysis Confirms Medication is as Effective as Surgery for Acid Reflux

Agency hopes to inform healthcare providers and patients about comparisons of treatments for gastroesophagealreflux disease.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=267131

72 - Los Angeles Facility Discontinues Use of OraQuick Rapid HIV Test

A recent spate of false positive results using OraSure’s test has officials and company representatives scrambling to figure out what is causing these anomalies and how to stop them from impacting testing rates.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=267129

73 - Study Will Compare Heart Risk of COX-2 and NSAIDs

Doctors and academics are praising Pfizer’s plan to allow the Cleveland Clinic to compare Celebrex with two NSAIDs. Is the company courageous, or is it taking to big of a risk?

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=267125

74 - Merck Will Lay Off 7,000 and Close Five Plants

The embattled pharma company needs to walk a tightrope between reassuring employees and pleasing investors. Can it succeed? Analysts and personnel experts share their insights.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=256387

75 - Microbiology Research Could Lead to Improved TB Treatment

A new understanding about how one class of bacteria protects itself from the environment could dramatically cut tuberculosis treatment time.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=256391

76 - Preclinical Goes Digital

The electronic revolution in clinical trials is still a work in progress, but researchers say it's time to bring EDC to the preclinical world.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=256390

77 - Animal Rights Activists Create PR Crisis

Animal-rights activists call for attacks on testing facilities. Congress calls activists terrorists. Industry leaders propose a response.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=211216

78 - What Really Happened to Pargluva

Pargluva was a bad bet from early on. Analysts say so. Can BMS still save face?

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=211215

79 - Patients Are Playing Doctor on the Web. It is a Whole New Game for Pharma.

Log on to CrazyMeds.org. Find out what patients say about your drugs, and what they think doctors and pharma don’t tell them.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=211213

80 - Advisory Committee Recommends Hepatitis A Vaccine for All Children

The success of a 1999 program to vaccinate children in high-risk areas against Hepatitis A prompted the Advisory Committee on Immunization Practices to recommend universal use. But the vaccine may face minor hurdles from insurance companies and states.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=196826

81 - Merck Wins Round Two

Legal experts analyze the differences between the first two Vioxx trials and what allowed Merck to be successful this time around. They also offer insight about what to expect going forward.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=196824

82 - FDA to Collaborate to Find Biomarker for Liver Toxicity

The Critical Path is alive and well, as demonstrated by an agreement between FDA and Massachusetts-based BG Medicine to identify molecules associated with liver toxicity in animal trials.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=196825

83 - Advisory Committee to Review OTC HIV Test

A look at the issues facing the Blood Products Advisory Committee when it reviews OraSure’s at-home test next month.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=188575

84 - Predicting the Success of HPV Vaccines

Will vaccines against cervical cancer be the blockbusters that Merck and GSK are predicting? Or will issues of cost-effectiveness and parental reluctance hold them back? The experts weigh in on the debate.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=188572

85 - Atypical Antipsychotics Increase Risk of Death for Dementia Patients

A new meta-analysis confirms the risk of atypical antipsychotics noted by FDA earlier this year. But the reasons for this increased incidence of death remain unclear.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=188574

86 - Predicting the Success of HPV Vaccines

Merck and GSK’s cervical cancer vaccines promise great benefits to women-but there are several key hurdles to clear before the drugs can become the blockbusters the companies are predicting. Analysts debate how long it will take it will take to overcome these obstacles.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=188573

87 - Generic AZT Hits the United States

A look at what the advent of generic antiretroviral drugs could mean for the industry.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=185696

88 - Human Genome Sciences Awarded Contract for Anthrax Drug

ABthrax takes advantage of new knowledge about anthrax to fight the bacteria’s lethal toxin.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=185691

89 - Blood Advisory Committee Recommends Exjade by Novartis

Experts are thrilled about the development of a new iron chelation drug that could be taken orally, changing the lives of patients who need chronic blood transfusions.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=185693

90 - Andrew von Eschenbach Appointed New Acting Head of FDA

Hours after Lester Crawford resigns, the head of the National Cancer Institute takes his place on the FDA hot seat.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=182292

91 - California Researchers Investigate Antibody-like Viral Protein

Scientists talk about the medical applications of a protein with 10 trillion possible functional variations. The molecule, present in viruses that infect bacteria, is the closest thing to an antibody ever discovered. And it might be easier to replicate.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=182291

92 - Anti-Inflammatory Treatment Could Change as a Result of New Findings on Nuclear Receptor Proteins

A University of California San Diego professor explains the results of his research on nuclear receptors and why these findings could lead to new therapies for autoimmune diseases.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=180135

93 - Arthritis Advisory Committee Recommends Orencia by Bristol-Myers Squibb

A look at the science behind a new class of rheumatoid arthritis drugs that act by suppressing an early stage of inflammation, the activation of T cells.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=180132

94 - Study Shows Faster Approval Does Not Affect Safety

Analysis of a new report that says safety-related product withdrawals have not increased since the approval process sped up in the 1990s.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=180133

95 - FDA Approves Genetic Test to Customize Dosage for Pfizer Cancer Drug

An ingenious pharmacogenetic test from Third Wave Technologies tests for the presence of a genetic change that inhibits metabolism of irinotecan. Oncology specialists explain how it works, and why it matters.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=177157

96 - Merck Found Liable in First Vioxx Trial

Legal experts play Monday-morning quarterback with Merck's first Vioxx loss. The lessons, they say: learn to present science better, pay attention to jury emotion and, oh yes, worry about shareholder lawsuits.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=177161

97 - Placebo Effect: All in the Brain

Scientists at the University of Michigan found a brain mechanism that increases the release of pain-fighting endorphins when the subject was given a placebo. The implication? Better clinical trials, and maybe, new methods of pain relief, researchers say.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=177155

98 - Acambis Working to Create a Universal Flu Vaccine

This vaccine specialist is attempting to create a product that will protect people from influenza A for every future flu season without re-formulation. They are thinking about how to fight influenza B, too.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=175382

99 - Pozen Files NDA Days After Advisory Committee Rejection

Migraine specialist abandons one problematic drug and maintains its position by filing an NDA the following week.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=175384

100 - Two New Techniques Make Genome Sequencing Faster and Cheaper

Only a year after the National Human Genome Research Institute called for improving sequencing technology, two new methods were announced in the same week. What will the goal of a $1000 human genome mean for medicine and disease research?

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=175383

101 - CAFTA Intellectual Property Provisions Stir Controversy

Generics manufacturers, public health advocates and Big Pharma square off over the implications of the Central American Free Trade Agreement.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=172835

102 - Teva Advances Generics Consolidation with Ivax Purchase

Teva's recent purchase of Ivax has analysts wondering where the push for bigger and more global generic manufacturing companies will take the industry.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=172831

103 - Sleep Aid with Novel Mechanism Approved

Experts offer their opinion on how Takeda's Rozerem, the first non-controlled sleep aid, will be received by doctors and patients.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=172828

104 - Brazil Uses Compulsory Licensing Threat in Negotiations

The possibility of Brazil compulsorily licensing Abbott Laboratory’s HIV/AIDS treatment Kaletra has re-awakened the debate how the World Trade Organization’s TRIPS agreement should be interpreted for the pharma industry. We asked experts to offer different viewpoints on this issue.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=170954

105 - Prescription Drug Addiction Study Recommends Marketing Sensitivity

Prescription drug abuse nearly doubled over a three-year period, according to a new report. In addition to the statistics that you may have seen elsewhere, the study’s authors recommend ways to curb this trend including submitting all promotional material for controlled drugs to FDA.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=170956

106 - Vision Problem Added to Labels for Viagra, Cialis, and Levitra

Exactly what is Nonarteritic Ischemic Optic Neuropathy and how might it be linked to the use of ED drugs?

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=170970

107 - Californians to Vote on Drug Discount Plan

Two ballot initiatives offer different methods for discounting prescription drugs in California. But what are the plans really promising? Get the details of each proposal and an analysis of efforts to sway California voters.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=168693

108 - GSK Inks Deal with Non-Profit to Develop AIDS Vaccine

The trend of public/private partnerships to combat diseases of the developing world continues with collaboration between GSK and the International AIDS Vaccine Initiative. We examine the details of the deal, the science GSK plans to use and the future of this trend.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=168699

109 - Supreme Court: Research Use of Patented Compounds OK

We asked top intellectual property lawyers about what the Supreme Courts decision will mean for pharma and biotech companies. Here is our forward-looking analysis of their comments.

www.pharmexec.com/pharmexec/content/contentDetail.jsp?id=168431